• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports Corner
 

Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports Corner

on

  • 443 views

Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, ...

Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, non-profitable biotech companies). The universe continues to grow despite the high risk and the wait to transform into a successful profitable Mature Biotech is long.

https://www.reportscorner.com/reports/10016/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Rising-Stars/

Statistics

Views

Total Views
443
Views on SlideShare
443
Embed Views
0

Actions

Likes
0
Downloads
5
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports Corner Global pharmaceutical & biotechnology outlook 2013 rising stars - Reports Corner Presentation Transcript

    • RCReports CornerGlobal Pharmaceutical & Biotechnology Outlook2013: Rising Stars
    • DescriptionDescriptionReports Cornerwww.reportscorner.comInnovative and improved drugs therapies developed throughnovel target discovery and technology platforms have originatedfrom the backyards of small research focused companies (RisingStars, RS, non-profitable biotech companies). The universecontinues to grow despite the high risk and the wait to transforminto a successful profitable Mature Biotech is long.
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comInnovative and improved drugs therapies developed throughnovel target discovery and technology platforms have originatedfrom the backyards of small research focused companies (RisingStars, RS, non-profitable biotech companies). The universecontinues to grow despite the high risk and the wait to transforminto a successful profitable Mature Biotech is long. 2012 saw newdrugs approvals for unmet needs, first in class drugs for Anti-obesity, Myelofibrosis, cancers and better drug options for HCV,RA, MS, psoriasis, HCC, dyslipidemia etc. We expect approval of"better drugs for bad bugs", targeted therapies for cancer,Alzheimers, antivirals and orphan diseases in the next five years.Despite negative outcome of pivotal clinical trials or ruling by theFDA, no one (investors and large pharma/biotech companies)have given up on innovation which is reflected in the healthy cashposition within the sector. Hope of resurrection will prevail in thenext five years and successful commercialization of anti-obesity,dyslipidemia etc. could boost the RS sector.
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe expectation bar of investors for M&A is on the rise and withseveral RS companies accepting the challenge of marketing drugson their own. Coming years will witness a mix of both-acquisitions as well as entering the Mature Biotech club. The racein innovations is killing newly launched novel drugs (ex. INCIVEKprotease inhibitor for HCV) and patents do not offer protectionfrom competition by better drugs in development. Diversifiedstrategies will be essential both for the small and big players tomitigate these challenges as the life cycle of new drugs may beshorter than before in some therapy areas.The New Avatars of Microbes is a growing threat world wide andwe expect "GAINS" for companies focused in the anti-infectivetherapy class. "Pill vs. Prick"- is gaining popularity as new oraloptions are entering the market for RA, Psoriasis, MS etc. Pricingand experience of patients and physicians will drive complianceand define market opportunity of these drugs.
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comOrphan disease focus will continue to remain attractive andsuccess of Eteplirsen (PhII, Sarepta) for the treatment ofDuchenne muscular dystrophy (DMD) and other antisense, RNAidrugs in the pipeline could see the final maturing ofoligonucleotide based drug therapies.Global Biopharmaceutical Outlook 2013 of the Rising Stars sectorreleased by MP Advisors provides an in depth analyses of biotechcompanies and their drug pipeline amidst competition anddynamic regulatory environment. The report discusses thecompetitive landscape of the targeted therapy areas and theinnovative strategy each company is deploying to surmountchallenges and remain attractive for acquisitions, partnerships ormarch toward profitability. Sum of parts valuations of drugs in thepipeline are included after factoring clinical development risksand competition.
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comRisk reward analyses of important upcoming milestones of thecompanies are included which should help fund managers as wellas pharma company management to make critical decisions.The detailed 109 pages report contains:Macro AnalysisReport Card of MP Advisors Recommendation of 2012Top Picks for 2013Select Drug Approval in 2011-12 and Drug Launches in 2013-14Select Mid To Late Stage Drug DisappointmentsCash Balance of Select RS CompaniesChallenges and Unmet Need of Innovators - Launched andPipeline Unpartnered CompoundsResisting resistance – Emergence of Bad Bugs – GAIN ActNew Targets And Drugs For Bad BugsSelect Mid To Late Stage Anti-Infective Pipeline For SeriousHospital Infections
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comRetrograde Evolution- Where Innovation is Killed by InnovatorsOral vs. Injectables - Select Oral RA Drugs in Development.In-depth Company Analysis and Reports onTop PicksCempra – GAIN from Drugs for Bad BugsGalapagos - GLPG0634 Excels vs. all JAK Inhibitors for RA.Incyte - JAKAFI/ JAKAVI Approved for Myelofibrosis and Drugs inPipeline –Drivers of GrowthMorphosys - Maturing Pipeline and Partnering/Acquisition in theOffingOutperformsArQule - Failure in NSCLC – Disappointing but Not "The End" forTivantinibBasilea - Ceftobiprole + Early Stage Pipeline Remains A FreeOption!Medivir - Simeprevir in the HCV Race - Value Un-Appreciated!
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comRigel - Be in SyK (for RA)– Positives Coming AheadSymBio - Novel Oncology Drug Portfolio Available as a Free CallOption!Trius - Partnering or Buy Out on the Cards.Vivus - Marketing Anti-obesity Drugs -Where Being First Has notHelpedMarket PerformsAmarin - VASCEPA – Left to Fend on its Own!Aveo - Tivozanib – Wait May be Longer!Halozyme - rHuPH20 Benefits for Chronic Use - Still UnderScrutinyImmunomedics - Lack of Catalysts in Near TermISIS - What More is Left Beyond KYNAMRO?Industry TablesDrug Clinical MilestonesDrug Launch Table- 2013NPV Valuation
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comMacro Analysis• Report Card of MP Advisors Recommendation of 2012• Top Picks for 2013• Select Drug Approval in 2011-12 and Drug Launches in 2013-14• Select Mid To Late Stage Drug Disappointments• Cash Balance of Select RS Companies• Challenges and Unmet Need of Innovators - Launched and Pipeline UnpartneredCompounds• Resisting resistance – Emergence of Bad Bugs – GAIN Act• New Targets And Drugs For Bad Bugs• Select Mid To Late Stage Anti-Infective Pipeline For Serious Hospital Infections• Retrograde Evolution- Where Innovation is Killed by Innovators• Oral vs. Injectables – Select Oral RA Drugs in Development.In-depth Company Analysis – Top Picks
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com1. Cempra (CEMP)1.1. Investment Drivers – Solithromycin, TAKSTA1.2. Unmet Need For Next Generation Macrolides1.3. Why Will Physicians Prescribe Solithromycin?1.4. Background1.5. Spectrum Of Activity Against Cabp Bacteria1.6. Clinical Updates – Solithromycin, TAKSTA1.7. Clinical Success Rates – Comparison With Linezolid Of Taksta1.8. Market Opportunity2. Galapagos (GLPG)2.1. Investment drivers2.2. unpartnered programs - GLPG0974, GLPG0187, CAM-12.3. Partnered programs - GLPG0778 / GLPG05552.4. Clinical Data Comparison – Select Oral RA Drugs3. Incyte (INCY)
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com3.1. Investment drivers – JAKAFI/JAKAVI3.2. JAKAFI – Label Expansion3.3. Competition to JAKAFI/ JAKAVI3.4. JAKs Potential in Autoimmune / Inflammation therapy area3.5. Other Mid- to Early-stage Pipeline3.6. Competitive Landscape: Myelofibrosis3.7. Clinical Data Comparison: Myelofibrosis3.8. Baricitinib: PhIII Studies Detail4. Morphosys (MOR)4.1. Investment drivers4.2. Latest development in pipeline products (unpartnered) – MOR103, MOR208,MOR2024.3. Latest development in pipeline products (partnered) – Gantenerumab, BHQ880,CNTO888
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comCompany analysisOutperforms1. ArQule (ARQL)1.1. Major Setback for Tivantinib in NSCLC1.2. Clinical Data – HCC, Other solid tumors1.3. Other Pipeline Products – ARQ736, ARQ621, ARQ0871.4. PhI Studies In Solid Tumors – Tivantinib2. Basilea (BSLN)2.1. Isavuconazole – Next Key Driver2.2. Ceftobiprole and Early Stage Programs – A Free Option2.3. Partnered Programs – Toctino, Isavuconazole2.4. Comparative Pharmacokinetics Of The Triazoles2.5. Competitive Landscape For Anti-Fungals2.6. Early-stage Pipeline2.7. Ceftobiprole – Chronology of events with FDA and MAA/CHMP
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com3. Medivir (MVIR)3.1. Positive on Approval of Simeprevir+IFN/RBV Combination3.2. Key Products In Pipeline: IFN-Free Combination3.3. Simeprevir – Ongoing PhIII Trials4. Rigel (RIGL)4.1. Investment driver – Fostamatinib4.2. Fostamatinib: OSKIRA – PhIII Clinical Trials Designs4.3. Select Oral RA Drugs In Development4.4. Other Compounds in DevelopmenT – R343, R333, R548, R3484.5. Clinical Data Comparison – Select Oral RA Drugs5. SymBio (4582 JP)5.1. Upside from SymBios portfolio – TREAKISYM5.2. Pipeline – Rigosertib, Anti-emetic Transdermal Patch5.3. Symbio Product Portfolio
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com5.4. Background5.5. Competition From Key Marketed Drugs in CLL, MDS AND NHL5.6. Competition From Drugs in the Pipeline For CLL, NHL and RRMM inJAPAN/ASIA5.7. PI3K Inhibitors in Development5.8. Data Presented At ASH 12 of Bendamustine5.9. Data Presented At ASH 12 of Regosertib6. Trius (TSRX)6.1. Market Opportunity of Tedizolid in ABBBSI6.2. Other Indications – Tedizolid6.3. Clinical Updates – Tedizolid6.4. MRSA Infection – Competitive Landscape6.5. Clinical Data in ABSSSI/ cSSSI of Select Antibiotics6.6. Top-Line Data From the TR701-112 Trial in ABSSSI
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com6.7. Collaborations7. Vivus (VVUS)7.1. Reimbursement Strategies Are Slowly Falling in Place – Qnexa7.2. Stendra – Wait for a Marketing Partner May Be Rewarded Soon7.3. Qysmia in patients with moderate to severe Obstructive Sleep Apnea (OSA)7.4. Weight Loss And Safety Profile ComparisonMarket Performs1. Amarin (AMRN)1.1. Clean Label Highlights Clinical Benefits1.2. Strong IP has not been able to neutralize the concern around NCE/NME decision1.3. Commercializing strategy1.4. Manufacturing and Global Supply Chain1.5. Competitive Analysis: VASCEPA vs. LOVAZA & EPANOVA1.6. Clinical Data Comparison in Hypertriglyceridemia – VASCEPA vs. LOVAZA &EPANOVA
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com2. Aveo (AVEO)2.1. Updated data at European Society for Medical Oncology (ESMO 12)2.2. Data presented from TIVO-1 study at ASCO 122.3. Ongoing Trials for Tivozanib2.4. Competitive Landscape: Advanced Renal Cell Carcinoma3. Halozyme (HALO)3.1. Baxter and CSL Have Competing SC Versions of Immunoglobulins3.2. 2nd Generation Herceptin Could Limit the Opportunity for Herceptin SC3.3. Biosimilar and Biobetters Could Stem MabThera SC (Rituxan) Opportunity3.4. Upside from Unpartnered Products: Limited Opportunity3.5. Biosimilars in Development4. Immunomedics (IMMU)4.1. Key Pipeline Products – Epratuzumab, 90YClivatuzumab+gemcitabine,Veltuzumab4.2. Antibody-Drug Conjugate (ADC) Programs
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com4.3. Product Pipeline4.4. Technology Platforms4.5. Competitive Landscape: Lupus5. ISIS (ISIS)5.1. KYNAMRO – Negative CHMP and Risk Highlighted by EMDAC5.2. Partnership – AZN, BIIB, GSK5.3. Other Late-/ Mid-stage Programs - OncogeneX/ Tevas OGX-011/TV-1011,OncogeneXs OGX-427, ISIS ISIS-EIF4ERx,5.4. Competitive Landscape: Familial HypercholesterolemiaIndustry Tables1. Drug Clinical Milestones2. Drug Launch Table- 20133. NPV Valuation
    • For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websitehttps://www.reportscorner.com/reports/10016/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Rising-Stars/
    • Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com